

How to isolate and analyse microvesicles in human samples?

Editorial for the contribution of M-A. Azerad et al, entitled: Microvesicles and cancer

F. Mullier, N. Bailly, C. Chatelain, B. Chatelain, J-M. Dogné

(Belg J Hematol 2013;1:9-10)

In this edition of the Belgian Journal of Hematology, Azerad et al. discuss the definition, analysis and roles of microparticles/microvesicles (MVs) in cancer. Microvesicles are small spherical structures highly heterogeneous both in size and in composition.^{1,2} As stated by Azerad, the MV nomenclature is still a matter of debate since there is no consensus on size distribution due to inaccuracy and imprecision of size measurement.^{1,3} As potential disease biomarkers, MV measurement and characterisation in biological fluids could reveal new diagnostic and/or prognostic information in human diseases.^{4,5} Currently, the detection and quantification of MVs are hampered by their methods of isolation and their nanometric size.⁶⁻⁸ Therefore, the validation and standardisation of sensitive characterisation techniques are needed. This is challenging since a wide range of pre-analytical variables including blood sampling, sample handling, plasma generation, and plasma freezing/storing are considered as major sources of variability and potential artefacts in MV analysis. Briefly, after gentle transport, 109mM citrated whole blood should be centrifuged at room temperature within 30min to 1h to isolate plasma, with a light brake only. A double centrifugation step at 2,500g is recommended to ensure removal of platelets and decrease platelet

MV production during subsequent freeze/thawing. Samples processed fresh and those frozen prior to analysis should not be directly compared. In addition, frozen-thawed plasma should ideally be stored for an equal length of time and no more than one year. This information is often lacking and should be clearly highlighted.⁹⁻¹¹

As indicated by Azerad., no 'gold standard' technique is recognized so far to characterize MVs. Each method has specific advantages and drawbacks. Inter-laboratory comparisons are currently not possible due to absence of appropriate biological MV preparations ('calibrators') with well defined characteristics (i.e. size distribution, concentration). Flow cytometry (FCM) remains the technique most used to quantify MVs and give insight into the cellular origin. FCM suffers from a lack of sensitivity for small size MVs (size<500nm) although recent improvements provided access to previously undetectable MVs (lower size limit: 200-300nm).¹² It is unknown if looking at smaller MVs will give additional biological information.¹³ Submicron polystyrene beads are interesting tools in FCM to help in qualifying instruments and measure a reproducible part of the largest MVs.¹⁴ However, absolute sizing of MVs using scatter parameters and polystyrene beads also presents drawbacks.¹⁵⁻¹⁷ Interestingly, the use of specific protocols

Authors: F. Mullier, Pr^{1,2}, N. Bailly², C. Chatelain, Pr³, B. Chatelain, Pr², J-M. Dogné, Pr¹. ¹Department of Pharmacy, NARILIS, Namur Thrombosis and Hemostasis Center (NTHC), University of Namur, Belgium. ²Laboratory of Hematology, NARILIS, Namur Thrombosis and Hemostasis Center (NTHC), CHU UCL Mont-Godinne-Dinant, Université Catholique de Louvain, Belgium. ³Department of Hematology, NARILIS, Namur Thrombosis and Hemostasis Center (NTHC), CHU UCL Mont-Godinne-Dinant, Université Catholique de Louvain, Belgium. Please send all correspondence to: F. Mullier, Pr, NARILIS, CHU UCL Mont-Godinne-Dinant, Université Catholique de Louvain, Laboratory of Hematology, 1 Avenue Gaston Therasse, B5530 Yvoir, Belgium, tel: +32 81 423243, fax: +32 81 423204, email: mullierfrancois@gmail.com.

Conflict of interest: The authors have nothing to disclose and indicate no potential conflict of interest.

on different instruments decreases inter-instrument variability.¹⁸ Whatever the instrument type, optimal scatter resolution may vary in-time and between individual instruments and should be regularly checked. Efforts should focus on the development and validation of biological calibrators to compare the sensitivity of different technologies and instruments.¹⁵⁻¹⁷ Important advances in FCM confirm their interest as a competitive analytical method to measure MVs of smaller size in comparison with other technologies such as atomic force microscopy and nanoparticle tracking analysis.^{6,19,20} These alternative technologies are promising options for the characterisation of small size MVs.^{6,20}

Acknowledgments

This work was supported by a grant from Le Fonds pour la formation à la Recherche dans l'Industrie et dans l'Agriculture (FRIA).

References

1. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. *Nature reviews Immunology*. 2009 Aug;9(8):581-93.
2. Gyorgy B, Szabo TG, Pasztoi M, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. *Cellular and molecular life sciences: CMLS*. 2011 Aug;68(16):2667-88.
3. Van der Pol E, Hoekstra AG, Sturk A, et al. Optical and non-optical methods for detection and characterization of microparticles and exosomes. *J Thromb Haemost*. 2010 Dec; 8(12):2596-607.
4. Mullier F, Bailly N, Cornet Y, et al. Contribution of platelet microparticles generation assay to the diagnosis of type II heparin-induced thrombocytopenia. *Thrombosis and haemostasis* 2010 Jun;103(6):1277-81.
5. Mullier F, Lainey E, Fenneteau O, et al. Additional erythrocytic and reticulocytic parameters helpful for diagnosis of hereditary spherocytosis: results of a multicentre study. *Annals of hematology*. 2011 Jul;90(7):759-68.
6. Ashcroft BA, de Sonnevile J, Yuana Y, et al. Determination of the size distribution of blood microparticles directly in plasma using atomic force microscopy and microfluidics. *Biomed Microdevices*. 2012 Mar 6.
7. Jayachandran M, Miller VM, Heit JA, et al. Methodology for isolation, identification and characterization of microvesicles in peripheral blood. *J Immunol Methods*. 2012 Jan 31;375(1-2):207-14.
8. Lacroix R, Judicone C, Poncelet P, et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. *J Thromb Haemost*. 2012 Mar;10(3):437-46.
9. Ayers L, Kohler M, Harrison P, et al. Measurement of circulating cell-derived microparticles by flow cytometry: sources of variability within the assay. *Thrombosis research*. 2011 Apr;127(4):370-7.
10. Lacroix R, Judicone C, Poncelet P, et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. *J Thromb Haemost*. 2011 Dec 28.
11. Yuana Y, Bertina RM, Osanto S. Pre-analytical and analytical issues in the analysis of blood microparticles. *Thrombosis and haemostasis*. 2011 Mar;105(3):396-408.
12. Robert S, Lacroix R, Poncelet P, et al. High-Sensitivity Flow Cytometry Provides Access to Standardized Measurement of Small-Size Microparticles. *Arteriosclerosis, thrombosis, and vascular biology*. 2012 Feb 9.
13. Freyssinet JM, Toti F. Membrane microparticle determination: at least seeing what's being sized! *J Thromb Haemost*. 2010 Feb;8(2):311-4.
14. Lacroix R, Robert S, Poncelet P, et al. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. *J Thromb Haemost*. Nov; 8(11):2571-4.
15. Chandler WL, Yeung W, Tait JF. A new microparticle size calibration standard for use in measuring smaller microparticles using a new flow cytometer. *J Thromb Haemost*. 2011 Jun;9(6):1216-24.
16. Mullier F, Bailly N, Chatelain C, et al. More on: calibration for the measurement of microparticles: needs, interests, and limitations of calibrated polystyrene beads for flow cytometry-based quantification of biological microparticles. *J Thromb Haemost*. 2011 Aug;9(8):1679-81.
17. Robert S, Poncelet P, Lacroix R, et al. More on: calibration for the measurement of microparticles: value of calibrated polystyrene beads for flow cytometry-based sizing of biological microparticles. *J Thromb Haemost*. 2011 Aug; 9(8):1676-8; author reply 81-2.
18. Poncelet P, Faussat A-M, Gameiro C, et al. Abstracts of the XXIII Congress of the International Society on Thrombosis and Haemostasis with the 57th Annual SSC (Scientific and Standardization Committee) Meeting. July 23-28 2011. Kyoto, Japan. *J Thromb Haemost*. 2011 Jul;9 Suppl 2:897.
19. Dignat-George F, editor. Minutes of the Vascular Biology Working Group on the Measurement of microparticles by flow cytometry. International Society of Thrombosis and Hemostasis 2011; Kyoto.
20. Filipe V, Hawe A, Jiskoot W. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. *Pharmaceutical research*. 2010 May;27(5):796-810.